Literature DB >> 21533758

Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control.

Daniel Zips1, Simon Böke, Theresa Kroeber, Andreas Meinzer, Kerstin Brüchner, Howard D Thames, Michael Baumann, Ala Yaromina.   

Abstract

BACKGROUND AND
PURPOSE: Previous experiments showed that the fraction of radiobiologically hypoxic tumor cells (rHF) in un-treated tumors did not accurately predict local tumor control after fractionated irradiation. Thus, the prognostic value of rHF determined during fractionated irradiation was investigated.
MATERIALS AND METHODS: Six human squamous cell carcinoma lines were transplanted into nude mice and then irradiated with 15 fractions over 3 weeks. Thereafter, single dose irradiation under normal and clamped blood flow was given. Local tumor control rates were used to calculate the rHF and the TCD₅₀, i.e., the radiation dose necessary to control 50% of the tumors, after single dose irradiation. These values were compared with the in parallel determined TCD₅₀ after 30 fractions in 6 weeks.
RESULTS: The rHF after 15 fractions varied between 28% and 100%. No correlation was found with the TCD₅₀ after 30 fractions in 6 weeks. Single dose top-up TCD₅₀ under ambient and clamp conditions after 15 fractions significantly correlated with TCD₅₀ after 30 fractions in 6 weeks.
CONCLUSION: rHF after 15 fractions is not a prognostic parameter for the outcome after fractionated irradiation. In contrast, the radiobiological parameters number of tumor stem cells, intrinsic radiosensitivity, and number of radiobiologically hypoxic tumor cells appear promising to predict outcome after fractionated irradiation.

Entities:  

Mesh:

Year:  2011        PMID: 21533758     DOI: 10.1007/s00066-011-2210-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  19 in total

1.  Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by gammaH2AX staining.

Authors:  Apostolos Menegakis; Ala Yaromina; Wolfgang Eicheler; Annegret Dörfler; Bettina Beuthien-Baumann; Howard D Thames; Michael Baumann; Mechthild Krause
Journal:  Int J Radiat Biol       Date:  2009-11       Impact factor: 2.694

2.  Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC).

Authors:  Dirk Rades; Cornelia Setter; Juergen Dunst; Olav Dahl; Steven E Schild; Frank Noack
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

3.  Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts.

Authors:  Ala Yaromina; Theresa Kroeber; Andreas Meinzer; Simon Boeke; Howard Thames; Michael Baumann; Daniel Zips
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-12       Impact factor: 7.038

4.  Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies.

Authors:  Ala Yaromina; Daniel Zips; Howard D Thames; Wolfgang Eicheler; Mechthild Krause; Andrea Rosner; Michael Haase; Cordula Petersen; James A Raleigh; Verena Quennet; Stefan Walenta; Wolfgang Mueller-Klieser; Michael Baumann
Journal:  Radiother Oncol       Date:  2006-09-07       Impact factor: 6.280

5.  Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters.

Authors:  Matthias Kappler; Helge Taubert; Hans-Jürgen Holzhausen; Rolf Reddemann; Swetlann Rot; Axel Becker; Thomas Kuhnt; Kathrin Dellas; Jürgen Dunst; Dirk Vordermark; Gabriele Hänsgen; Matthias Bache
Journal:  Strahlenther Onkol       Date:  2008-08       Impact factor: 3.621

Review 6.  Tumor microenvironmental physiology and its implications for radiation oncology.

Authors:  Peter Vaupel
Journal:  Semin Radiat Oncol       Date:  2004-07       Impact factor: 5.934

7.  Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data.

Authors:  J E Moulder; S Rockwell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-05       Impact factor: 7.038

8.  Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer.

Authors:  Kathrin Dellas; Matthias Bache; Steffi U Pigorsch; Helge Taubert; Matthias Kappler; Daniel Holzapfel; Ester Zorn; Hans-Juergen Holzhausen; Gabriele Haensgen
Journal:  Strahlenther Onkol       Date:  2008-03       Impact factor: 3.621

9.  Correlation of pretreatment polarographically measured oxygen pressures with quantified contrast-enhanced power doppler ultrasonography in spontaneous canine tumors and their impact on outcome after radiation therapy.

Authors:  Carla Rohrer Bley; Dagmar Laluhova; Malgorzata Roos; Barbara Kaser-Hotz; Stefanie Ohlerth
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

10.  Hypoxia and reoxygenation in human melanoma xenografts.

Authors:  E K Rofstad
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-07       Impact factor: 7.038

View more
  20 in total

1.  [Translational uroradio-oncology].

Authors:  S E Combs; J Debus
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

2.  Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines.

Authors:  D Schilling; C Bayer; K Emmerich; M Molls; P Vaupel; R M Huber; G Multhoff
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

Review 3.  [Experimental tumor therapy].

Authors:  M Baumann; D Zips; M Krause
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

Review 4.  Profiles of Radioresistance Mechanisms in Prostate Cancer.

Authors:  Luksana Chaiswing; Heidi L Weiss; Rani D Jayswal; Daret K St Clair; Natasha Kyprianou
Journal:  Crit Rev Oncog       Date:  2018

Review 5.  Radiation oncology in the era of precision medicine.

Authors:  Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal:  Nat Rev Cancer       Date:  2016-03-18       Impact factor: 60.716

6.  Effects of three modifiers of glycolysis on ATP, lactate, hypoxia, and growth in human tumor cell lines in vivo.

Authors:  A Yaromina; S Meyer; C Fabian; K Zaleska; U G A Sattler; L A Kunz-Schughart; W Mueller-Klieser; D Zips; M Baumann
Journal:  Strahlenther Onkol       Date:  2012-02-16       Impact factor: 3.621

7.  Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: a 10-year experience at a single institution.

Authors:  Giampiero Ausili Céfaro; Domenico Genovesi; Annamaria Vinciguerra; Marianna Trignani; Maria Taraborrelli; Antonietta Augurio; Roberto Buonaguidi; Renato J Galzio; Marta Di Nicola
Journal:  Strahlenther Onkol       Date:  2011-11-25       Impact factor: 3.621

8.  Dichloroacetate induces tumor-specific radiosensitivity in vitro but attenuates radiation-induced tumor growth delay in vivo.

Authors:  F Zwicker; A Kirsner; P Peschke; F Roeder; J Debus; P E Huber; K J Weber
Journal:  Strahlenther Onkol       Date:  2013-06-23       Impact factor: 3.621

9.  The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer.

Authors:  Christian Ostheimer; Franziska Schweyer; Thomas Reese; Matthias Bache; Dirk Vordermark
Journal:  Oncol Lett       Date:  2016-09-08       Impact factor: 2.967

10.  A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.

Authors:  C Ostheimer; M Bache; A Güttler; M Kotzsch; D Vordermark
Journal:  Strahlenther Onkol       Date:  2013-12-11       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.